Feodoroff, Maija
,
Harjutsalo, Valma
Forsblom, Carol
Groop, Per-Henrik
Funding for this research was provided by:
Diabetes Research Foundation
NovoNordisk Foundation
Suomen Akatemia (134379)
Signe ja Ane Gyllenbergin Säätiö
Liv och Hälsa Foundation
Päivikki ja Sakari Sohlbergin Säätiö
Folkhälsan Research Foundation
Finska Läkaresällskapet
Wilhelm and Else Stockmann Foundation
Article History
Received: 4 February 2018
Accepted: 2 August 2018
First Online: 18 September 2018
Duality of interest
: P-HG has received investigator-initiated research grants from Eli Lilly and Roche, is an advisory board member for AbbVie, Astra Zeneca, Boehringer-Ingelheim, Eli Lilly, Janssen, Medscape, MSD, Novartis, Novo Nordisk and Sanofi, and has been an advisory board member for Cebix. He has received lecture fees from Astra Zeneca, Boehringer-Ingelheim, Eli Lilly, ELO Water, Genzyme, Medscape, MSD, Novartis, Novo Nordisk and Sanofi. All other authors declare that there is no duality of interest associated with this manuscript.